129 related articles for article (PubMed ID: 37075717)
21. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cortes J; Mauro M; Steegmann JL; Saglio G; Malhotra R; Ukropec JA; Wallis NT
Am J Hematol; 2015 Apr; 90(4):E66-72. PubMed ID: 25580915
[TBL] [Abstract][Full Text] [Related]
23. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
25. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
26. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
28. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
[TBL] [Abstract][Full Text] [Related]
29. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.
Levy M; Xie L; Wang Y; Neumann F; Srivastava S; Naranjo D; Xu J; Zhang Q; Dalal M
Cancer Treat Res Commun; 2021; 28():100424. PubMed ID: 34198039
[TBL] [Abstract][Full Text] [Related]
30. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Yang J; Surapaneni M; Schiffer CA
Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
[TBL] [Abstract][Full Text] [Related]
32. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
[TBL] [Abstract][Full Text] [Related]
33. Management of ponatinib dosing in chronic myeloid leukemia patients.
Sacha T; Szczepanek E
J Physiol Pharmacol; 2021 Jun; 72(3):. PubMed ID: 34810285
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
Cirmi S; El Abd A; Letinier L; Navarra M; Salvo F
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235443
[TBL] [Abstract][Full Text] [Related]
35. [Vascular adverse events of ponatinib during treatment of Philadelphia chromosome-positive leukemia: a retrospective single-institution analysis].
Sato N; Yuda J; Yamauchi N; Miyamoto K; Kamihara Y; Minami Y
Rinsho Ketsueki; 2019; 60(12):1623-1629. PubMed ID: 31902811
[TBL] [Abstract][Full Text] [Related]
36. Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Amin SO; Ruzicka M; Burns KD; Bence-Bruckler IA; Ryan SE; Hadziomerovic A; Hiremath S
J Clin Hypertens (Greenwich); 2020 Apr; 22(4):678-682. PubMed ID: 32175644
[TBL] [Abstract][Full Text] [Related]
37. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
Pulte ED; Chen H; Price LSL; Gudi R; Li H; Okusanya OO; Ma L; Rodriguez L; Vallejo J; Norsworthy KJ; de Claro RA; Theoret MR; Pazdur R
Oncologist; 2022 Mar; 27(2):149-157. PubMed ID: 35641211
[TBL] [Abstract][Full Text] [Related]
39. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
Santoro M; Accurso V; Mancuso S; Contrino AD; Sardo M; Novo G; Di Piazza F; Perez A; Russo A; Siragusa S
Chemotherapy; 2019; 64(4):205-209. PubMed ID: 31825920
[TBL] [Abstract][Full Text] [Related]
40. Ponatinib-associated panniculitis: Case report and review of the literature.
Antwi-Amoabeng D; Ghuman J; Ghuman J; Beutler BD; Ulanja MB; Kuriakose K; Bowman A
Cancer Treat Res Commun; 2021; 27():100357. PubMed ID: 33756173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
